Suppr超能文献

用于跨医疗保健系统进行成本计算的基准方法:乳腺癌护理中每位患者每天的护理成本。

Benchmark Method for Cost Computations Across Health Care Systems: Cost of Care per Patient per Day in Breast Cancer Care.

机构信息

Stanford Cancer Institute, Stanford University School of Medicine, Stanford, CA.

Clinical Excellence Research Center, Stanford University School of Medicine, Stanford, CA.

出版信息

JCO Oncol Pract. 2021 Oct;17(10):e1403-e1412. doi: 10.1200/OP.20.00462. Epub 2021 Mar 1.

Abstract

PURPOSE

To estimate the value of cancer care and to compare value among episodes of care, a transparent, reproducible, and standardized cost computation methodology is needed. Charges, claims, and reimbursements are related to cost but are nontransparent and proprietary. We developed a method to measure the cost of the following phases of care: (1) initial treatment with curative intent, (2) surveillance and survivorship care, and (3) relapse and end-of-life care.

METHODS

We combined clinical data from our electronic health record, the state cancer registry, and the Social Security Death Index. We analyzed the care of patients with breast cancer and mapped Common Procedural Terminology (CPT) codes to the corresponding cost conversion factor and date in the CMS Medicare fee schedule. To account for varying duration of episodes of care, we computed a cost of care per day (CCPD) for each patient.

RESULTS

Median CCPD for initial treatment was $29.45 in US dollars (USD), the CCPD for surveillance and survivorship care was $2.45 USD, and the CCPD for relapse care was $13.80 USD. Among the three breast cancer types (hormone receptor-positive or human epidermal growth factor receptor 2 [HER2]-negative, HER2-positive, and triple-negative), there was no difference in CCPD. Relapsed patients in the most expensive surveillance CCPD group had significantly shorter survival.

CONCLUSION

We developed a method to identify high-value oncology care-cost of care per patient per day (CCPD)-in episodes of initial, survivorship, and relapse care. The methodology can help identify positive deviants (who have developed best practices) delivering high-value care. Merging our data with claims data from third-party payers can increase the accuracy and validity of the CCPD.

摘要

目的

为了评估癌症护理的价值并比较护理期间的价值,需要一种透明、可重复和标准化的成本计算方法。费用、索赔和报销与成本有关,但不透明且专有的。我们开发了一种方法来衡量以下护理阶段的成本:(1)有治愈意图的初始治疗,(2)监测和生存护理,以及(3)复发和临终关怀。

方法

我们结合了来自电子健康记录、州癌症登记处和社会保障死亡指数的临床数据。我们分析了乳腺癌患者的护理情况,并将常见程序术语 (CPT) 代码映射到 CMS 医疗保险费用表中的相应成本转换因子和日期。为了考虑护理期间的持续时间不同,我们为每位患者计算了护理成本/天 (CCPD)。

结果

初始治疗的 CCPD 中位数为 29.45 美元(USD),监测和生存护理的 CCPD 为 2.45 美元,复发护理的 CCPD 为 13.80 美元。在三种乳腺癌类型(激素受体阳性或人表皮生长因子受体 2 [HER2] 阴性、HER2 阳性和三阴性)中,CCPD 没有差异。在监测 CCPD 费用最高的复发患者中,生存时间明显缩短。

结论

我们开发了一种方法来确定初始、生存和复发护理期间每个患者每天的高价值肿瘤护理成本(CCPD)。该方法可以帮助确定提供高价值护理的正偏离者(已制定最佳实践)。将我们的数据与第三方付款人的索赔数据合并,可以提高 CCPD 的准确性和有效性。

相似文献

1
Benchmark Method for Cost Computations Across Health Care Systems: Cost of Care per Patient per Day in Breast Cancer Care.
JCO Oncol Pract. 2021 Oct;17(10):e1403-e1412. doi: 10.1200/OP.20.00462. Epub 2021 Mar 1.
2
Computing the Cost of Care per Patient per Day for Patients With Metastatic Neuroendocrine Neoplasms.
JCO Oncol Pract. 2024 Feb;20(2):203-211. doi: 10.1200/OP.23.00433. Epub 2023 Dec 14.
6
What Is the Value of Undergoing Surgery for Spinal Metastases at Dedicated Cancer Centers?
Clin Orthop Relat Res. 2021 Jun 1;479(6):1311-1319. doi: 10.1097/CORR.0000000000001640.
7
Evaluating the Addition of Clinical and Staging Data to Improve the Pricing Methodology of the Oncology Care Model.
JCO Oncol Pract. 2022 Nov;18(11):e1899-e1907. doi: 10.1200/OP.22.00211. Epub 2022 Oct 17.
8
Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance.
Eur Urol Open Sci. 2021 Jan;23:20-29. doi: 10.1016/j.euros.2020.11.004. Epub 2020 Dec 10.

引用本文的文献

1
Computing the Cost of Care per Patient per Day for Patients With Metastatic Neuroendocrine Neoplasms.
JCO Oncol Pract. 2024 Feb;20(2):203-211. doi: 10.1200/OP.23.00433. Epub 2023 Dec 14.
2
Breast Cancer Diagnosis, Treatment, and Outcomes of Patients From Sex and Gender Minority Groups.
JAMA Oncol. 2023 Apr 1;9(4):473-480. doi: 10.1001/jamaoncol.2022.7146.

本文引用的文献

1
Real-world Evidence to Estimate Prostate Cancer Costs for First-line Treatment or Active Surveillance.
Eur Urol Open Sci. 2021 Jan;23:20-29. doi: 10.1016/j.euros.2020.11.004. Epub 2020 Dec 10.
3
Updated Overview of the SEER-Medicare Data: Enhanced Content and Applications.
J Natl Cancer Inst Monogr. 2020 May 1;2020(55):3-13. doi: 10.1093/jncimonographs/lgz029.
4
Prediction Models - Development, Evaluation, and Clinical Application.
N Engl J Med. 2020 Apr 23;382(17):1583-1586. doi: 10.1056/NEJMp2000589.
5
Exploring Care Attributes of Nephrologists Ranking Favorably on Measures of Value.
J Am Soc Nephrol. 2019 Dec;30(12):2464-2472. doi: 10.1681/ASN.2019030219. Epub 2019 Nov 14.
7
Spending for Advanced Cancer Diagnoses: Comparing Recurrent Versus De Novo Stage IV Disease.
J Oncol Pract. 2019 Jul;15(7):e616-e627. doi: 10.1200/JOP.19.00004. Epub 2019 May 20.
8
Critical Lessons From High-Value Oncology Practices.
JAMA Oncol. 2018 Feb 1;4(2):164-171. doi: 10.1001/jamaoncol.2017.3803.
9
Exploring Attributes of High-Value Primary Care.
Ann Fam Med. 2017 Nov;15(6):529-534. doi: 10.1370/afm.2153.
10
The Future Awakens: A Report on the 2016 Vizient Clinical Connections Summit.
Am J Med Qual. 2017 May/Jun;32(1_suppl):3S-30S. doi: 10.1177/1062860617701070.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验